Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.70 |
| ▸ | MEN1 | O00255 | 7/20 | 0.70 |
| ▸ | GFER | P55789 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MITF | O75030 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12189436 | 0.92 | MEN1 (0.64) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL9799698 | 0.85 | MEN1 (0.61) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL10836873 | 0.85 | KMT2A (0.72) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL13927135 | 0.85 | ALDH1A1 (0.92) | KMT2AMEN1GFERPOLBMITF | |
| SCHEMBL2702303 | 0.84 | NPC1 (0.71) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL31155757 | 0.84 | CHRNB2 (0.69) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL15740330 | 0.84 | MEN1 (0.68) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL18132369 | 0.83 | KMT2A (0.62) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL14075408 | 0.83 | MEN1 (0.72) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL25063320 | 0.83 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | COL2A1, BMP4, BMP2 | MAPT 4575/4885SMN1; SMN2 3908/4885NPC1 3340/4885 |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, BMP2 | MAPT 4575/4885SMN1; SMN2 3908/4885NPC1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.